Venture Visionary Partners LLC Increases Stake in Amgen Inc. $AMGN

Venture Visionary Partners LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 82.0% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 39,896 shares of the medical research company’s stock after purchasing an additional 17,976 shares during the period. Venture Visionary Partners LLC’s holdings in Amgen were worth $11,139,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of AMGN. Smith Chas P & Associates PA Cpas lifted its stake in Amgen by 2.1% during the 2nd quarter. Smith Chas P & Associates PA Cpas now owns 116,729 shares of the medical research company’s stock valued at $32,592,000 after acquiring an additional 2,378 shares during the period. Baron Silver Stevens Financial Advisors LLC lifted its stake in Amgen by 10.8% during the 2nd quarter. Baron Silver Stevens Financial Advisors LLC now owns 927 shares of the medical research company’s stock valued at $259,000 after acquiring an additional 90 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH lifted its stake in Amgen by 16.2% during the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 5,786 shares of the medical research company’s stock valued at $1,616,000 after acquiring an additional 806 shares during the period. Moss Adams Wealth Advisors LLC lifted its stake in Amgen by 1.8% during the 2nd quarter. Moss Adams Wealth Advisors LLC now owns 3,348 shares of the medical research company’s stock valued at $935,000 after acquiring an additional 59 shares during the period. Finally, GC Wealth Management RIA LLC lifted its stake in Amgen by 77.3% during the 2nd quarter. GC Wealth Management RIA LLC now owns 8,287 shares of the medical research company’s stock valued at $2,314,000 after acquiring an additional 3,614 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.69% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on AMGN shares. Raymond James Financial started coverage on shares of Amgen in a research note on Wednesday, September 3rd. They set a “market perform” rating on the stock. Bank of America upped their target price on shares of Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research note on Friday. William Blair restated an “outperform” rating on shares of Amgen in a research note on Tuesday, June 24th. Piper Sandler upped their target price on shares of Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research note on Monday, August 25th. Finally, UBS Group lowered their target price on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 6th. Seven analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has an average rating of “Hold” and an average price target of $309.70.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $272.98 on Monday. The firm’s 50 day moving average price is $288.86 and its 200-day moving average price is $288.89. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $335.88. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The stock has a market capitalization of $146.96 billion, a PE ratio of 22.32, a price-to-earnings-growth ratio of 2.37 and a beta of 0.49.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.18 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the prior year, the business earned $4.97 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were paid a dividend of $2.38 per share. The ex-dividend date was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a yield of 3.5%. Amgen’s dividend payout ratio (DPR) is presently 77.84%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.